カテゴリ： Allied Market Research, 世界, 医療/バイオ

世界の神経変性治療薬市場2021年-2031年：薬物クラス別（ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他）、疾患別（パーキンソン病、アルツハイマー病、多発性硬化症、その他）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局）

■ 英語タイトル：Neurodegenerative Drugs Market By Drug Class (Dopamine agonist , Decarboxylase inhibitors , Cholinesterase Inhibitors , Immunomodulators, Others ), By Indication (Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis , Others), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23JUN072）

■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23JUN072
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：300
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）

■ 販売価格オプション（消費税別）

Online Only（1名閲覧、印刷不可）	USD3,570 ⇒換算￥542,640	見積依頼/購入/質問フォーム
Single User（1名閲覧）	USD5,730 ⇒換算￥870,960	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）	USD9,600 ⇒換算￥1,459,200	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界の神経変性治療薬市場2021年-2031年：薬物クラス別（ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他）、疾患別（パーキンソン病、アルツハイマー病、多発性硬化症、その他）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局）]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

Allied Market Research社は、2021年には36,277.20百万ドルであった世界の神経変性治療薬市場規模が2031年には74,809.38百万ドルへ上り、予測期間中（2022-2031）に年平均7.5％成長すると見込んでいます。本書では、神経変性治療薬の世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、薬物クラス別（ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他）分析、疾患別（パーキンソン病、アルツハイマー病、多発性硬化症、その他）分析、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などの項目について分析した内容を調査書にまとめました。また、市場調査の対象企業には、F. Hoffmann-La Roche Ltd.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Ltd.、Orion Corporation、Biogen、Sanofi、Viatris Inc.、Novartis AG、UCB S.A.、AbbVie Inc.などの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の神経変性治療薬市場規模：薬物クラス別
- ドパミン作動薬の市場規模
- 脱炭酸酵素阻害薬の市場規模
- コリンエステラーゼ阻害薬の市場規模
- 免疫調節薬の市場規模
- その他神経変性治療薬の市場規模
・世界の神経変性治療薬市場規模：疾患別
- パーキンソン病における市場規模
- アルツハイマー病における市場規模
- 多発性硬化症における市場規模
- その他疾患における市場規模
・世界の神経変性治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
・世界の神経変性治療薬市場規模：地域別
- 北米の神経変性治療薬市場規模
- ヨーロッパの神経変性治療薬市場規模
- アジア太平洋の神経変性治療薬市場規模
- 中南米/中東・アフリカの神経変性治療薬市場規模
・競争状況
・企業情報

神経変性治療薬市場は、2021年に362億7,720万ドルと評価され、2031年には748億9,938万ドルに達すると予測されます。2022年から2031年までの年平均成長率は7.5%となる見込みです。
神経変性疾患とは、主に脳や脊髄のニューロン（神経細胞）が侵され、徐々に変性していく疾患群を指します。これらの疾患は通常、進行性で慢性的であり、時間とともに症状が悪化します。神経変性疾患の例としては、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症（ALS）、多発性硬化症（MS）などがあります。これらの疾患は、人の認知機能、運動機能、感覚機能に重大な影響を及ぼし、最終的には身体障害や死に至る可能性があります。

神経変性疾患の治療に使用される薬剤は、疾患の進行を遅らせたり、症状を緩和したりするためのものです。使用される具体的な薬剤は、治療対象となる神経変性疾患の種類によって異なります。例えば、アルツハイマー病の治療に使用される薬剤にはコリンエステラーゼ阻害剤やメマンチンなどがあり、パーキンソン病の治療に使用される薬剤にはレボドパ、ドーパミン作動薬、MAO-B阻害剤などがあります。
神経変性治療薬の世界市場の成長を牽引する主な要因は、神経変性疾患に伴う症状をコントロールするための先進的な薬剤に対する需要の増加です。さらに、神経変性疾患に対する強力なパイプラインが市場の主要なトレンドであり、これが市場の成長を促進すると期待されています。患者数の大幅な増加が薬剤の需要増につながっています。しかし、医薬品開発プロセスに伴う合併症や医薬品の副作用が市場成長の妨げになると予想されます。

一方、未開拓の新興国における高い成長ポテンシャル、多発性硬化症治療薬BAF312やオレラブルチニブなどのパイプライン製品の増加、神経変性疾患の継続的な医薬品承認は、市場プレイヤーに有利な機会を提供すると予想されます。例えば、2020年1月、Novartis AGは、欧州委員会（EC）が、再発または炎症活動の画像的特徴によって証明される活動性の二次性進行性多発性硬化症（SPMS）の成人患者の治療薬としてメイゼント（シポニモド）を承認したと発表しました。

神経変性治療薬市場は、薬剤クラス、疾患、流通チャネル、地域に区分されます。
薬剤クラス別では、ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他に分類されます。
疾患別では、パーキンソン病、アルツハイマー病、多発性硬化症、その他に分類されます。
流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、インド、オーストラリア、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に区分して分析しています。

神経変性治療薬の世界市場で事業を展開する主な主要企業は、AbbVie Inc.、Biogen、F. Hoffmann-La Roche Ltd.、Novartis AG、Orion Corporation、Sanofi、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Viatris Inc.、UCB S.A.です。同市場で事業を展開する主要企業は、企業研修市場シェアを拡大するための主要戦略として、製品承認、買収、提携、合意を採用しています。

ステークホルダーにとっての主な利点
・本レポートは、2021年から2031年にかけての神経変性治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、有力な神経変性治療薬市場機会を特定します。
・主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・神経変性治療薬市場のセグメンテーションを詳細に分析し、市場機会を特定します。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界の神経変性治療薬の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

〈主要市場セグメント〉
薬剤クラス別
ドーパミン作動薬
脱炭酸酵素阻害薬
コリンエステラーゼ阻害薬
免疫調節薬
その他

疾患別
パーキンソン病
アルツハイマー病
多発性硬化症
その他

流通チャネル別
病院薬局
オンラインプロバイダー
ドラッグストア・薬局

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Orion Corporation
Biogen
Sanofi
Viatris Inc.
Novartis AG
UCB S.A.
AbbVie Inc.

*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of neurodegenerative diseases
3.4.1.2. Initiatives by government and non-government organizations
3.4.1.3. Expected launch of new drugs during the forecast period

3.4.2. Restraints
3.4.2.1. Complications associated with drug development

3.4.3. Opportunities
3.4.3.1. Increase in R&D activities

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Dopamine agonist
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Decarboxylase inhibitors
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cholinesterase Inhibitors
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Immunomodulators
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Parkinson’s Disease
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Alzheimer’s Disease
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Multiple Sclerosis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Class
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Class
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Class
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Class
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Class
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Class
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Class
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Class
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Class
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Class
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Class
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Class
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Class
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Class
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Class
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Class
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Class
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Class
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Class
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. AbbVie Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Teva Pharmaceutical Industries Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Orion Corporation
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. UCB S.A.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Viatris Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Biogen
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY REGION, 2021-2031 ($MILLION)
TABLE 03. NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
TABLE 04. NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
TABLE 05. NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 08. NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 09. NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY REGION, 2021-2031 ($MILLION)
TABLE 11. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 13. NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 16. NEURODEGENERATIVE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 18. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. U.S. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 23. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 25. CANADA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 26. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 29. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 32. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 36. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 39. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. UK NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. UK NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 42. UK NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. ITALY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 45. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 48. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 51. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 56. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 58. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 64. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 69. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 70. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 76. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 78. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 80. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 83. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 86. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 89. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. NOVARTIS AG: KEY EXECUTIVES
TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY STRATERGIES
TABLE 95. ABBVIE INC.: KEY EXECUTIVES
TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 99. ABBVIE INC.: KEY STRATERGIES
TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 109. SANOFI: KEY EXECUTIVES
TABLE 110. SANOFI: COMPANY SNAPSHOT
TABLE 111. SANOFI: PRODUCT SEGMENTS
TABLE 112. SANOFI: PRODUCT PORTFOLIO
TABLE 113. ORION CORPORATION: KEY EXECUTIVES
TABLE 114. ORION CORPORATION: COMPANY SNAPSHOT
TABLE 115. ORION CORPORATION: PRODUCT SEGMENTS
TABLE 116. ORION CORPORATION: PRODUCT PORTFOLIO
TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 121. UCB S.A.: KEY EXECUTIVES
TABLE 122. UCB S.A.: COMPANY SNAPSHOT
TABLE 123. UCB S.A.: PRODUCT SEGMENTS
TABLE 124. UCB S.A.: PRODUCT PORTFOLIO
TABLE 125. UCB S.A.: KEY STRATERGIES
TABLE 126. VIATRIS INC.: KEY EXECUTIVES
TABLE 127. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 128. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 129. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 130. BIOGEN: KEY EXECUTIVES
TABLE 131. BIOGEN: COMPANY SNAPSHOT
TABLE 132. BIOGEN: PRODUCT SEGMENTS
TABLE 133. BIOGEN: PRODUCT PORTFOLIO
TABLE 134. BIOGEN: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

グローバル市場調査会社